摘要
背景:糖尿病2型(DMT2)是一种全球性的内分泌疾病,目前全球12个成年人中有1个受到影响,患病率仍在增加。世界卫生组织(世卫组织)宣布,作为一种流行病,这一世界范围内的健康问题将成为唯一具有这种分类的非传染性疾病。 DMT2患者出现各种并发症的风险增加,预期寿命缩短。目前可用于DMT2的主要口服降糖药物的化学组成,作用方式,安全性和耐受性各不相同。 方法:系统地搜索同行评审的科学文献和公共数据库。我们列入了最新的相关研究论文和数据,涉及本次审查的重点。使用标准工具评估检索到的论文的质量。 结果:该综述突出了具有共同靶点-DMT2的分子的化学结构多样性。所谓的传统抗糖尿病药以及最新和最少探索的药物包括多肽和氨基酸衍生物(胰岛素,胰高血糖素样肽1,二肽基肽酶-IV抑制剂,胰淀素),磺酰脲衍生物,苄基噻唑烷-2,4-二酮(过氧化物酶体增殖物激活受体-γ激动剂/格列酮类),缩合胍基核心(二甲双胍)和糖样分子(α-葡糖苷酶和钠/葡萄糖共转运蛋白2抑制剂)。 结论:随着糖尿病成为更常见的疾病,对新药理靶点的兴趣正在上升。
关键词: DMT2,过氧化物酶体增殖物激活受体-γ激动剂,二甲双胍,α-葡糖苷酶抑制剂,胰高血糖素样肽1类似物,二肽基肽酶-IV抑制剂,胰岛淀粉样多肽类似物,钠 - 葡萄糖协同转运蛋白2抑制剂。
Current Medicinal Chemistry
Title:Antidiabetics: Structural Diversity of Molecules with a Common Aim
Volume: 25 Issue: 18
关键词: DMT2,过氧化物酶体增殖物激活受体-γ激动剂,二甲双胍,α-葡糖苷酶抑制剂,胰高血糖素样肽1类似物,二肽基肽酶-IV抑制剂,胰岛淀粉样多肽类似物,钠 - 葡萄糖协同转运蛋白2抑制剂。
摘要: Background: Diabetes mellitus type 2 (DMT2) is an endocrine disease of global proportions which is currently affecting 1 in 12 adults in the world, with still increasing prevalence. World Health Organization (WHO) declared this worldwide health problem, as an epidemic disease, to be the only non-infectious disease with such categorization. People with DMT2 are at increased risk of various complications and have shorter life expectancy. The main classes of oral antidiabetic drugs accessible today for DMT2 vary in their chemical composition, modes of action, safety profiles and tolerability.
Methods: A systematic search of peer-reviewed scientific literature and public databases has been conducted. We included the most recent relevant research papers and data in respect to the focus of the present review. The quality of retrieved papers was assessed using standard tools.
Results: The review highlights the chemical structural diversity of the molecules that have the common target-DMT2. So-called traditional antidiabetics as well as the newest and the least explored drugs include polypeptides and amino acid derivatives (insulin, glucagon-like peptide 1, dipeptidyl peptidase-IV inhibitors, amylin), sulfonylurea derivatives, benzylthiazolidine- 2,4-diones (peroxisome proliferator activated receptor-γ agonists/glitazones), condensed guanido core (metformin) and sugar-like molecules (α-glucosidase and sodium/ glucose co-transporter 2 inhibitors).
Conclusion: As diabetes becomes a more common disease, interest in new pharmacological targets is on the rise.
Export Options
About this article
Cite this article as:
Antidiabetics: Structural Diversity of Molecules with a Common Aim, Current Medicinal Chemistry 2018; 25 (18) . https://dx.doi.org/10.2174/0929867325666171205145309
DOI https://dx.doi.org/10.2174/0929867325666171205145309 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Differences in Metabolic Syndrome – A Key Research Issue
Endocrine, Metabolic & Immune Disorders - Drug Targets Greener Liquid Chromatography for Simultaneous Determination of Rosiglitazone and Glimepiride in Rat Sera and its Application to a Pharmacokinetic Study
Current Analytical Chemistry Vascular and Cellular Calcium in Normal and Hypertensive Pregnancy
Current Clinical Pharmacology The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Radiological Diagnosis of Renal Thrombosis in Children
Current Pediatric Reviews Evaluation of Anti-Diabetic and Anti-Hyperlipidemic Activity of Isolated Bioactive Compounds of Leaves of <i>Annona reticulata</i> Linn.
The Natural Products Journal Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction
Current Pharmaceutical Design Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design The Therapeutic Role of Renin-Angiotensin System Blockers in Obesity- Related Renal Disorders
Current Clinical Pharmacology Endoplasmic Reticulum Stress Inhibition Enhances Liver Tolerance to Ischemia/Reperfusion
Current Medicinal Chemistry Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Current Vascular Pharmacology Peptide Inhibitors of a-Amylase Based on Tendamistat: Development of Analogues with ϖ-Amino Acids Linking Critical Binding Segments
Protein & Peptide Letters Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Management of Measurable Variable Cardiovascular Disease' Risk Factors
Current Cardiology Reviews Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design